NASDAQ
Halozyme Therapeutics, Inc. (HALO) has a free cash flow growth of -18.96% as of Friday, May 29, 2026. This represents a 239.86% decrease compared to its 12-month average of 13.56%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.